Research Article

Related GMR Articles

07/24/2014
BRCA1; Clinical outcome; Non-small cell lung cancer; RRM1

This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. In total, 377 patients agreed to participate in our study, and all of them received platinum-based combination chemotherapy between January 2008 and ... more

J.G. Liang; Z.Y. Jin; X.D. Gao; M.R. Te; L.H. Ge; C.L. Wang
01/26/2015
Non-small cell lung cancer; Overall survival; Progression; Xeroderma pigmentosum group G

We conducted a cohort study to investigate whether 3 potential single nucleotide polymorphisms (SNPs) in the xeroderma pigmentosum complementation group G (XPG) gene could predict the survival of advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based doublet chemotherapy. We enrolled 262 patients with histologically confirmed NSCLC between November 2007 ... more

H.Z. Zou; Y.Q. Zhao
01/22/2013
High-resolution melting analysis; Lung cancer; Non-small cell lung cancer; Risk factor; Single nucleotide polymorphism

Although lung cancer (LC) is a highly environmentally associated disease, genetic factors are also thought to play a role in this disease. In recent years, genome-wide association studies have identified various susceptible genetic regions for LC. Herein, we used high-resolution melting analysis to genotype 2 significant single nucleotide polymorphisms previously reported in Caucasians, ... more

H. Wang; Y. Zhao; J. Ma; G. Zhang; Y. Mu; G. Qi; Z. Fang; L. Wang; Q. Fan; Z. Ma
10/31/2014
Clinical characteristics; Mutation; Non-small cell lung cancer; Oncogene; Radical resection

More than 40 oncogenes associated with non-small cell lung cancer (NSCLC) have been identified with varied gene expression. The correlations between specific clinical characteristics and oncogene expression in NSCLC patients were examined. From October 2011 to September 2012, a total of 60 patients with NSCLC (male:female, 34:24; mean age, 59.5 ± 10.6 years; age range, 31-81 years) were ... more

Y. Han; D.P. Yu; S.J. Zhou; X.Y. Song; Y.S. Li; N. Xiao; Z.D. Liu; X.J. Sun; Q.Y. Zhao; S.K. Liu
04/17/2015
Brain metastasis; Non-small cell lung cancer; Polymorphism; TGFB1

We conducted a case-control study to investigate the role of 3 single-nucleotide polymorphisms of the gene encoding transforming growth factor-b1 (TGFB1) in the development of metastatic brain tumors in non-small cell lung cancer patients. The polymorphisms in TGFB1 rs4803455, rs1800469, and rs1800470 were evaluated by polymerase chain reaction-restriction fragment ... more

H.B. Wang; W.G. Song; H.Q. Liu; F. Fang; Y. Xiao
08/26/2011
Non-small cell lung cancer; Polymorphisms; STAT3

Signal transducer and activator of transcription protein 3 (STAT3) has been implicated in cancer development and is recognized as a type of oncogene. However, association studies of single nucleotide polymorphisms (SNPs) in the STAT3 gene with cancer risk are rare and not available for lung cancer. We examined whether STAT3 polymorphisms are associated with the risk of ... more

B. Jiang; Z.Z. Zhu; F. Liu; L.J. Yang; W.Y. Zhang; H.H. Yuan; J.G. Wang; X.H. Hu; G. Huang
09/27/2013
Biomarker; Gene polymorphism; Genetics; Non-small cell lung cancer; Survivin

Lung cancer is the most common cancer worldwide. Survivin is one of the first reported inhibitors of apoptosis proteins, which is an important family of proteins that regulate apoptosis. The survivin gene is located on human chromosome 17q25, which is composed of 142 amino acids. A common polymorphism of the survivin gene promoter -31G/C has been shown to influence cancer risk. This ... more

E. Aynaci; E. Coskunpinar; A. Eren; O. Kum; Y.M. Oltulu; N. Akkaya; A. Turna; I. Yaylim; P. Yildiz
12/04/2014
Excision repair cross-complementing group 1; mRNA; Non-small cell lung cancer; Response to chemotherapy; Ribonucleotide reductase subunit M1; Survival

We conducted a prospective study to analyze the expression of the excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) genes in 297 Chinese patients with advanced non-small cell lung cancer (NSCLC). The goal of this study was to evaluate these genes as potential biomarkers for prediction of tumor response and clinical outcome ... more

H. Zhang; J. Li; Y. Zhang; M. Sun; P. Zhao; G. Zhang; C. Jin; L. Sun; M. He; B. Wang; X. Zhang
10/31/2014
Chemotherapy; Excision repair cross-complementation group 1; Non-small cell lung cancer; Single nucleotide polymorphism; Survival time

We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair cross-complementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were ... more

H. Gao; R.C. Ge; H.Y. Liu; Y. Wang; S. Yan
04/17/2014
ERCC5; Non-small cell lung cancer; SNPs; XRCC1

We aimed to assess the role of polymorphisms of the XRCC1 Arg194Trp, XRCC1 Arg399Gln, ERCC5 His1104Asp, and ERCC5 His46His genes on clinical outcomes of advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy regimens. A total of 378 NSCLC patients were asked to participate within 1 month after diagnosis between January 2005 and January 2006, and they ... more

D. Liu; J. Wu; G.Y. Shi; H.F. Zhou; Y. Yu

Pages